Peptide Therapy Labs and Monitoring: How a Protocol Is Built, Tracked and Adjusted

Start here if you are new to this: our main guide to peptide therapy in Ann Arbor covers what peptide therapy is, who it helps, safety and cost. This article is narrower on purpose. It is about the blood work.

The difference between a supervised peptide protocol and an unsupervised one is not the vial. It is the monitoring. Labs are what turn a prescription into a protocol: they establish whether a peptide is even the right tool, they give you a number to measure response against, and they catch the small number of things that need dose changes.

Why a Peptide Protocol Starts With a Blood Draw

Two reasons, and the first matters more than patients expect.

The first is diagnostic. A large share of the complaints that bring people to peptide therapy - flat energy, slow recovery, poor sleep, a stubborn shift in body composition - are driven by something a blood draw will find. Thyroid dysfunction, iron deficiency, low vitamin D, an untreated hormone deficiency, early insulin resistance, or a quietly elevated inflammatory marker. Prescribing a signaling peptide on top of an unaddressed deficiency treats the wrong layer. A consultation that ends with "this is a thyroid problem, not a peptide problem" is a good outcome.

The second is a baseline. Without a starting number, there is no way to distinguish a protocol that is working from a good month. Peptides are prescription medications prescribed and supervised by a clinician, and supervision means measurement.

The Baseline Panel and What Each Part Is For

Panels are individualized to your history and the compounds under consideration, drawn through LabCorp or Quest. A typical baseline for a peptide protocol covers five areas:

• The growth hormone axis. IGF-1 is the workhorse marker. Growth hormone itself is released in pulses and a single random draw tells you very little; IGF-1 integrates that output over days, which is why it is the number tracked on secretagogue protocols.
• Metabolic health. Fasting glucose, HbA1c, fasting insulin, and a lipid panel. This establishes insulin sensitivity before anything is started and gives a clean comparison later.
• Full hormone panel. Total and free testosterone, estradiol, SHBG, LH and FSH, a full thyroid panel including free T4 and free T3, prolactin, and a morning cortisol where the history warrants it. Hormonal deficiency is frequently the actual driver of symptoms patients attribute to aging, which is why hormone optimization and peptide protocols are so often assessed together.
• Inflammation and organ function. A complete blood count, comprehensive metabolic panel with liver and kidney markers, and hs-CRP.
• Common deficiencies. Ferritin and iron studies, vitamin D, and vitamin B12 where indicated. These are unglamorous and they explain a surprising number of "my recovery has collapsed" presentations.

IGF-1: The Number That Does Most of the Work

On growth hormone secretagogues, IGF-1 is where response shows up, and the published pharmacology explains why it is worth watching rather than assuming.

According to PubMed, in a randomized placebo-controlled trial in healthy adults, a single subcutaneous dose of the long-acting GHRH analog CJC-1295 produced dose-dependent increases in growth hormone of 2- to 10-fold lasting six days or more, and increases in IGF-1 of 1.5- to 3-fold lasting nine to eleven days. After multiple doses, mean IGF-1 remained above baseline for up to 28 days (Teichman et al., 2006; PMID 16352683, doi:10.1210/jc.2005-1536). In the pooled phase 3 tesamorelin trials, mean IGF-1 rose by 108 ng/mL against a 7 ng/mL fall on placebo (Falutz et al., 2010; PMID 20554713, doi:10.1210/jc.2010-0490).

Two practical consequences. First, these compounds have long tails, so lab timing relative to your last dose has to be consistent or the number is not comparable. Second, the goal is a physiologic IGF-1 for your age and sex, not the highest number achievable. An IGF-1 climbing out of range is a reason to reduce the dose, and that is a decision a lab result makes, not a symptom diary.

Glucose, Because Growth Hormone Touches Insulin Sensitivity

Growth hormone influences glucose handling, so glucose markers are followed on secretagogue protocols as a matter of routine rather than because a problem is expected. The available trial data is reassuring on this point: across 26 and 52 weeks of tesamorelin in phase 3, no clinically meaningful between-group differences in glucose parameters were observed (Falutz et al., 2010; PMID 20554713). Monitoring means you would know early if your own numbers moved.

Cortisol and Prolactin: Why Compound Selection Matters

Not every growth hormone secretagogue behaves the same way at the pituitary, and that is a monitoring question as much as a prescribing one.

According to PubMed, in the pharmacology study that introduced it, ipamorelin released growth hormone without raising ACTH or cortisol even at doses more than 200-fold above the dose producing half-maximal growth hormone release, while two comparator secretagogues did raise both. None of the compounds tested affected FSH, LH, prolactin or TSH (Raun et al., 1998; PMID 9849822, doi:10.1530/eje.0.1390552). That work was done in rats and swine, so it is a selectivity profile rather than a human outcome, but it is a real and useful reason to prefer one compound over another for a given patient. If you are weighing options, see our comparisons of tesamorelin, sermorelin and ipamorelin and CJC-1295 vs sermorelin, or the sermorelin service page.

The Follow-Up Schedule

Protocols here are built in stages rather than dispensed from a menu:

1. Consultation. Symptoms, history, training and recovery patterns, and what you are actually trying to achieve. Available in the Ann Arbor office or by telehealth anywhere in Michigan.
2. Baseline labs. Drawn before anything is prescribed, and reviewed with you rather than filed.
3. Protocol design and written informed consent. Compound selection, dosing and cycling built around your labs and goals, with the evidence behind each recommendation explained plainly, including where that evidence is thin.
4. Repeat labs and clinical review. Follow-up panels with symptom tracking, and a full outcomes review at three months. Nothing is set once and forgotten.

Timelines differ by compound. Sleep and recovery changes are typically reported earliest, often within two to six weeks. Body composition and tissue repair operate on a longer timeline. Individual results vary based on baseline labs, protocol design and lifestyle factors, and no specific outcome is guaranteed.

What Actually Triggers a Change

A protocol is adjusted, not admired. The common triggers:

• IGF-1 rising above the physiologic range for your age and sex, or failing to move at all after an adequate trial.
• A meaningful drift in fasting glucose, HbA1c or fasting insulin.
• New or persistent side effects, including fluid retention, joint discomfort, injection-site reactions, or numbness and tingling in the hands.
• Symptoms that have not changed by the review point. If nothing has happened, the honest options are to change the protocol or stop it, not to extend it indefinitely.
• A new diagnosis, pregnancy, or a new medication that changes the risk calculation.

What Labs Cannot Tell You

Blood work is necessary and it is not sufficient. There is no marker for how well you slept, how your tendon feels on a run, or whether your training is progressing. Symptom tracking sits alongside the panels, and where the two disagree, both get taken seriously.

There is also no lab that validates a compound with thin human evidence. A normal follow-up panel tells you a protocol is being tolerated. It does not tell you an investigational compound is working, and it is worth being clear about that distinction. Our write-up on peptides for injury recovery and tissue repair goes through where that evidence currently stands.

Frequently Asked Questions About Peptide Labs and Monitoring

Do I have to do labs if I feel fine?

Yes. Any patient unwilling to complete baseline labs and ongoing monitoring is not a candidate here. That is not a policy for its own sake - without a baseline there is no way to dose responsibly or to know whether to continue.

Where is the blood drawn?

Through LabCorp or Quest, which means you can use a location convenient to you rather than coming to the clinic for a draw.

How often are labs repeated?

It depends on the compound and your baseline. A common pattern is a follow-up panel in the first several weeks to months, then a full outcomes review with repeat labs at three months, then at intervals set by your response.

Does insurance cover peptide therapy or the labs?

Arbour Longevity operates on a cash-pay basis, which allows longer appointments and treatment decisions driven by clinical judgment rather than insurance formularies. HSA and FSA funds are accepted, and detailed receipts are available for potential out-of-network reimbursement. Your first visit is $35, applied toward your treatment plan.

Can monitoring be done by telehealth?

Yes. Initial and follow-up peptide consultations are available by telehealth for patients throughout Michigan, with labs drawn locally. Procedures requiring an in-person visit are performed at the Ann Arbor clinic. See our guide to peptide therapy across Michigan for how statewide access works.

What if the labs say peptides are not the answer?

Then that is the answer, and it is a useful one. Frequently the finding is a thyroid, iron, vitamin D or hormone issue that responds to something simpler and cheaper.

Talk to a Clinician Who Will Show You the Numbers

Peptide therapy is a real and genuinely promising area of medicine that has been badly served by the way it is marketed. The monitoring is what separates a clinical protocol from an experiment on yourself.

Arbour Longevity is led by Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC, a triple board certified nurse practitioner. Your first visit is $35, applied toward your treatment plan. Call or text (734) 436-3357. 2217 Packard St #15, Ann Arbor, MI 48104. Open Thursday to Monday, 10:00-19:00, closed Tuesday and Wednesday. Parking is free and directly outside, with no meters and no structure; Suite 15 is down a flight of stairs, so call ahead if stairs are difficult. Serving Ann Arbor, Dexter, Saline, Ypsilanti and Southeast Michigan, with telehealth statewide. Full service detail is on the peptide therapy in Ann Arbor page and the wider peptide program.

References

• Teichman SL, et al. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. PMID 16352683. doi:10.1210/jc.2005-1536
• Falutz J, et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor analog, in patients with excess abdominal fat: pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291-4304. PMID 20554713. doi:10.1210/jc.2010-0490
• Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PMID 9849822. doi:10.1530/eje.0.1390552
• Van Cauter E, et al. (2004). Reciprocal interactions between the GH axis and sleep. Growth Hormone & IGF Research, 14 Suppl A, S10-17. PMID 15135771. doi:10.1016/j.ghir.2004.03.006

Citations verified via PubMed. This article is educational and does not replace individualized medical advice. Peptides are prescription medications prescribed and supervised by a clinician. Laboratory panels are individualized and the examples above are illustrative, not a fixed protocol. Availability and regulatory status are subject to change, and individual results vary. Arbour Longevity, 2217 Packard St #15, Ann Arbor, MI 48104, (734) 436-3357.